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A satellite meeting on lactate was organized during the 8th
International Symposium on Shock and Critical Care, August
2001, Bali, Indonesia. The aim of the symposium was to
highlight lactate from a different standpoint to the classical
view of being a prognosis marker, often solely considered by
many physicians involved in intensive care medicine. The
review papers on lactate in the present issue discuss four of
the lectures presented in this symposium by Cano [1],
Bellomo [2], Iscra et al. [3], and Schurr [4].
Lactic acid, which is mostly present in biological fluids as its
dissociated cationic form (lactate–), is widely distributed
among the pathways involved in the intermediary metabolism
of living systems. While, from the physiologist point of view, it
is one of the most crucial intermediates of carbohydrate and
nonessential amino acid metabolisms, for most physicians it
is merely considered as a marker of bad prognosis
significantly related to a high mortality rate in acutely ill
patients [5–7]. Although several works in the literature have
shown the safety, and sometimes the usefulness, of
administration of exogenous lactate [8–13], it is very often
considered a highly ‘toxic’ compound. Even in sport
physiology, the ‘lactic threshold’ as a marker demonstrating a
sharp switch from aerobic to anaerobic metabolism is very
popular, and lactate increase is often believed to be the
cause of side effects observed after exhausting exercise
[14,15].
When recently explaining the design of studies where
patients received a bolus of exogenous sodium–high lactate
to one of our friends, a very experienced physician from the
intensive care unit, his instant reaction was ‘in my institution, I
would never get an agreement from the ethical committee for
such a study involving exogenous sodium–high lactate
infusion’. Of course, it is easy to demonstrate that high
lactate infusion is actually safe, even in very sick patients [9];
it is indeed a metabolite like glucose, amino acids, fatty acids
or ketones. Nevertheless, lactate is often intuitively
considered as ‘the devil in metabolism’ by many physicians or
scientists, this probably resulting from confusion between
cause and consequence.
Lactate is alternatively consumed and produced in the body,
as is the case for every intermediate involved through the
vast circuit of the intercellular and interorgan metabolic
interplay. This notion is actually the basis of the concept of
‘milieu intérieur’ as described by the French physiologist
Claude Bernard more than a century ago. Hence, lactate can
be considered as a wastage product when released from one
cell, but it becomes a very useful substrate when taken up by
another cell [16,17]. In fact, the extent of lactate turnover in
vivo in humans is of a similar order of magnitude to that of
glucose, alanine or glutamine (i.e. it has one of the highest
recycling rates in the intermediary metabolism). The main
question therefore remains as to understanding precisely the
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Abstract
Most physicians involved in intensive care consider lactate solely as a deleterious metabolite,
responsible for high morbidity and bad prognosis in severe patients. For the physiologist, however,
lactate is a key metabolite, alternatively produced or consumed. Many studies in the literature have
infused animals or humans with exogenous lactate, demonstrating its safety and usefulness, but the
bad reputation of lactate is still widespread. The metabolic meaning of glucose–lactate cycling
exceeds its initial role described by Cori and Cori. According to recent works concerning lactate, it can
be predicted that a new role as a therapeutic agent will arise for this metabolite.
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role of lactate as one of the main actors of the energetic
homeostasis in both physiological and pathological
conditions [18].
Lactate is actually a metabolic ‘cul de sac’ because it is
metabolized by one single enzyme, lactate dehydrogenase.
But, since the first description many decades ago by Cori of
interorgan glucose–lactate recycling, it is clear that lactate
has a real physiological meaning. The role of energetic
shuttle is classically considered between organs responsible
for a net lactate release and the liver. Every organ is able to
release lactate because all cells contain the different
enzymes allowing the conversion of glucose into lactate;
pancreatic islets are an exception since they are deficient in
lactate dehydrogenase [19]. However quantitatively, muscle
and red blood cells are probably the main tissues in
physiological conditions, but other organs (such as the lung,
for instance [3]) could be of importance in pathological
states. The liver is often regarded as the main organ for
lactate disposal because of its prominent role in
gluconeogenesis. The kidney, although recognized for a long
time also as a gluconeogenic organ, has probably been
underestimated [1]. Moreover, it was recently shown that
even during the anhepatic phase occurring during liver
transplantation, plasma lactate was maintained at a higher
but constant value, indicating that the liver is not mandatory
for lactate clearance [20].
Lactate also appears to possess some specific effects
besides its role in redox and carbon shuttle between organs
involved in the global energy metabolism. Different interesting
works have emphasized a role of lactate in the brain as a
protective substrate not only in animal studies [4,21–23], but
also in humans [10,13]. The description of coordinated
glucose and lactate metabolisms between neurons and
astrocytes in relation to neuron excitation has revealed a new
and fascinating side of brain lactate metabolism [24,25].
Concerning heart metabolism and cardiovascular function, it
has recently been shown that lactate improves cardiac
function in a model of hemorrhagic shock [26]. Also,
sodium–lactate infusion in humans increases cardiac output
not only in postoperative patients [12], but also in
cardiogenic shock [9].
In conclusion, this satellite meeting led to the feeling that our
view of lactate will probably change in the near future.
Lactate, instead of being only considered as a marker of
severity in critically ill patients, might be a metabolite used as
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